Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy

NACompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Leukemia
Interventions
DRUG

Procrit (epoetin alfa)

Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01099202 - Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy | Biotech Hunter | Biotech Hunter